All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Did you miss ASH 2020? The Multiple Myeloma Hub attended the virtual 62nd ASH Annual Meeting & Exposition, December, 5–8 2020, and has developed two resources in collaboration with our Steering Committee on the abstracts presented regarding multiple myeloma (MM) that could impact your clinical practice in the near future.
In the first downloadable resource, 'practice-changing abstracts', you will find comments from the Multiple Myeloma Hub Steering Committee members about the role of autologous stem cell transplant in the era of novel agents, and the latest updates on new combinations and therapy-sequencing strategies to achieve deeper and more durable responses.
ASH 2020 | Practice-changing abstracts in multiple myeloma
If you would like to view the practice-changing abstracts from ASH 2020 and the expert opinions from our Steering Committee, please download the resource belowDownload here
Our second resource, 'breakthrough abstracts', covers the most exciting news about monitoring MM with less-invasive techniques and promising alternative targets to treat refractory disease. Discover underlying resistance mechanisms that could help to early identify relapse or fundament new drug combinations. Find here, the initial results obtained with novel targeted agents and the latest about BCMA-directed immunotherapies (bispecific antibodies and CAR T-cells) in clinical development.
ASH 2020 | Breakthrough abstracts in multiple myeloma
If you would like to view the breakthrough abstracts from ASH 2020 and the expert opinions from our Steering Committee, please download the resource belowDownload here
ASH 2022: Top abstracts in MM and other plasma cell dyscrasias
To help navigate the exciting content presented at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the Multiple Myeloma Hub Steering Committee members...
ASH 2021 abstracts: What’s hot in multiple myeloma?
To help navigate the exciting content being presented at the 63rd ASH Annual Meeting and Exposition, the Multiple Myeloma Hub Steering Committee members have provided their recommendations for the...
Subscribe to get the best content related to multiple myeloma delivered to your inbox